Company intelligence / Profile preview
iQure Pharma Inc.
Princeton, New Jersey, United Statesiqurepharma.com ↗
- Ownership
- Private
- Development stage
- Other
01
Overview
iQure Pharma's lead asset iQ-007 is a first-in-class EAAT2 Positive Allosteric Modulator (PAM) designed to address toxic levels of glutamate in the synaptic cleft. The company secured $4M funding in January 2025 to progress with a Phase 1 clinical trial for iQ-007. Previously, in October 2023, they raised $1.2M to progress with IND-enabling pivotal tox studies for iQ-007. The compound has successfully completed the NIH ETSP epilepsy screening program.[4][5]
- Therapeutic areas
- Neurology
- Modalities
- Small molecules
- Industry
- Biotech
02
Drug pipeline
4 assets3 more assets in the full pipeline.
Beyond the preview
Go deeper on iQure Pharma Inc..
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on iQure Pharma Inc..